Ghrelin and GHRP-6 therapeutically improved gastroparesis (delayed stomach emptying) in diabetic rats through gastric motility stimulation — positioning GH secretagogues as diabetic gastroparesis treatments.
Key findingGhrelin and GHRP-6 restored gastric emptying in streptozotocin-diabetic rats with gastroparesis, improving gastric motility through GHS-R activation —
What the researchers found
Ghrelin and GHRP-6 restored gastric emptying in streptozotocin-diabetic rats with gastroparesis, improving gastric motility through GHS-R activation — validating GH secretagogues as therapeutic agents for diabetic gastroparesis, a common and debilitating complication.
Why it matters
Relevant for ghrp, neuropeptides, gut-healing, diabetes.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Therapeutic effects of ghrelin and growth hormone releasing peptide 6 on gastroparesis in streptozotocin-induced diabetic guinea pigs in vivo and in vitro.
Chinese medical journal, 121(13), 1183-8
Citation
Qiu, Wen-cai; Wang, Zhi-gang; Wang, Wei-gang; Yan, Jun; Zheng, Qi. (2008). Therapeutic effects of ghrelin and growth hormone releasing peptide 6 on gastroparesis in streptozotocin-induced diabetic guinea pigs in vivo and in vitro.. Chinese medical journal, 121(13), 1183-8.